For more information visit the Company's website at www.freseniusmedicalcare.com. Disclaimer:This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncer ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, highlighted its recent series of sponsored physician training programs hosted at premier U.S. academic medical centers. Over the past several months, these intensive, hands-on courses at Tulane University and Columbia University have advanced the clinical proficiency o ...

Core Insights - IceCure Medical's ProSense® technology is positioned as a minimally invasive alternative for early-stage breast cancer treatment, emphasizing its effectiveness and superior cosmetic outcomes compared to traditional surgical methods [2][4][6]. Company Participation and Events - IceCure Medical participated in the European Society of Breast Imaging (EUSOBI) Congress 2025, where their workshop on cryoablation for breast cancer was filled to capacity, indicating strong interest in their technology [1][2][3]. Research and Clinical Findings - Five abstracts were presented at the EUSOBI Congress, showcasing independent studies on ProSense® for breast cancer cryoablation, highlighting its growing adoption in Europe [1][2][3]. - Dr. Francesca Pugliese received the Young Physician-Scientist Grant for her study on lesion conspicuity imaging as a potential noninvasive biomarker for treatment evaluation, which was selected as one of the top five abstracts [1][3]. ProSense® Technology - ProSense® utilizes liquid nitrogen to create large lethal zones for tumor destruction, applicable to various lesions including breast, kidney, lung, and liver [4][5][6]. - The system is designed to enhance patient and provider value by accelerating recovery, reducing pain, and minimizing surgical risks [5][6]. Clinical Efficacy - At 12 months, the cumulative complete response rate in the cryoablation group was 75.8%, with an overall disease control rate of 96.8%, demonstrating its effectiveness compared to hormone therapy [7]. - In a study comparing cryoablation alone, cryoablation plus hormone therapy, and hormone therapy alone, the combination group showed the highest tumor-free rate at 91.2% [7].

Core Viewpoint - Accuray Incorporated and the University of Wisconsin School of Medicine and Public Health have signed a memorandum of understanding (MOU) to collaborate on advancing online adaptive radiotherapy (OART) using Accuray's helical radiation treatment delivery platform, aiming to enhance personalized cancer care [1][2]. Group 1: Collaboration Details - The collaboration will focus on clinical research, education, training, and adaptive technology development to improve the personalization and precision of cancer treatment [1][2]. - Mu Young Lee, SVP of Research & Product Development at Accuray, emphasized the mutual goal of expanding the curative power of radiotherapy and making advanced treatment options feasible for clinical departments of all sizes [2]. Group 2: Technological Background - The University of Wisconsin–Madison developed the first helical radiation delivery platform, the TomoTherapy System, which introduced integrated 3D daily image-guidance with intensity-modulated radiation therapy (IG-IMRT) [3]. - Accuray has continued to enhance the helical platform to improve precision, accuracy, image quality, speed, versatility, and workflow efficiencies since the TomoTherapy System's introduction [3]. Group 3: Institutional Background - The University of Wisconsin School of Medicine and Public Health is recognized as a leading institution in health sciences education and research, employing over 5,600 faculty and staff and providing educational opportunities for nearly 3,000 students [5]. - The school ranked 9 among public medical schools for NIH funding in federal fiscal year 2024, highlighting its strong research capabilities [5].

Group 1: Company Overview - Mineral Resources Limited (MIN) is a diversified Australian mining company focused on lithium and iron ore extraction in Western Australia [1][2] - ResMed (RMD) specializes in medical equipment, particularly cloud-connectable CPAP machines for treating obstructive sleep apnea, and is headquartered in San Diego, California [3][4] Group 2: Business Operations - MIN provides mining and engineering services through its subsidiary, CSI Mining Services, which operates across Western Australia, Queensland, and the Northern Territory [2] - ResMed operates two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS), offering both medical equipment and software solutions for out-of-hospital care [4][5] Group 3: Financial Performance - MIN has experienced a revenue growth rate of 12.2% per year since 2021, reaching $5,278 million in FY24, but net profit has decreased from $1,270 million to $125 million, with a reported ROE of 3.2% [6][7] - RMD has seen a revenue growth rate of 13.6% per year since 2021, achieving $4,685 million in FY24, with net profit increasing from $475 million to $1,021 million, and a reported ROE of 22.7% [7]

Baird Medical's successful participation at the ATA meeting reinforces its commitment to collaborating with the global medical community to advance the standard of care for thyroid disease and improve patient outcomes worldwide. About Baird Medical Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, announced its succ ...

Accessibility StatementSkip Navigation GALWAY, Ireland, Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are fully and unconditionally guarant ...

Accessibility StatementSkip Navigation PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming European Association for Cardio- Thoracic Surgery (EACTS) Annual Meeting, the world's largest gathering for the global cardiothoracic community, taking place October 8–11, 2025 in Copenhagen, ...

Core Insights - Royal Philips is introducing innovative technologies in radiation oncology at the ASTRO 2025 Annual Meeting, including the Philips Rembra RT and Areta RT CT platforms, and the helium-free BlueSeal RT 1.5T MR system, aimed at enhancing patient-centered care and improving the efficiency of radiation therapy planning [1][6]. Group 1: CT Simulation Innovations - The new Rembra RT and Areta RT systems are designed to enhance cancer treatment planning by providing faster and more accurate imaging, with ultra-fast image reconstruction speeds of up to 106 images per second and a wide 85 cm extended field of view [3][4]. - These systems enable 91% of care teams to work more efficiently due to user-friendly touchscreen controls and advanced imaging capabilities that capture a full respiratory cycle in one scan [3][4]. Group 2: Remote Collaboration and Long-term Value - The systems facilitate remote collaboration for planning and training, allowing care teams to remain connected without the need for additional staffing, thus providing reliable long-term value to hospitals [4][5]. - Philips offers a Tube for Life Guarantee and a design that allows for 20 years of service, which helps hospitals manage costs effectively while ensuring high performance [4]. Group 3: Advancements in MR Technology - The BlueSeal RT system is a helium-free 1.5T MR system that enhances simulation confidence and reduces registration errors, crucial for protecting healthy organs during radiation therapy [6][7]. - This system supports MR-only imaging protocols that can be completed in as little as 10 minutes, improving patient comfort and overall experience [7][9]. Group 4: Industry Leadership and Future Directions - Philips has installed approximately 2,000 helium-free MR scanners worldwide, reinforcing its leadership in sustainable MR technology for radiation oncology [8][9]. - The company is collaborating with MVision AI to integrate AI-powered auto-segmentation software with its CT simulators, further enhancing the precision of radiation therapy planning [5].

Core Insights - Royal Philips is introducing innovative technologies in radiation oncology at the ASTRO 2025 Annual Meeting, including the Philips Rembra RT and Areta RT CT platforms, which enhance accuracy and efficiency in radiation therapy [4][10] - The new helium-free BlueSeal RT 1.5T MR system is designed to improve simulation confidence and sustainability in radiation oncology [10][12] CT Platforms - The Rembra RT and Areta RT systems are engineered to expedite cancer treatment planning, providing clearer images and ultra-fast image reconstruction speeds of up to 106 images per second [7][8] - These systems feature a wide 85 cm extended field of view and next-generation 4DCT imaging capabilities, capturing a full respiratory cycle in one scan [7][8] - The platforms support remote collaboration for planning and training, enhancing efficiency without the need for additional staff [8] MR System - The BlueSeal RT system utilizes AI-powered SmartSpeed Precise software, enabling enhanced simulation confidence and reducing registration errors [10][11] - With approximately 2,000 helium-free MR scanners installed globally, Philips is leading the transition to sustainable MR technology [12] - The lightweight design of BlueSeal RT allows for flexible installation in various clinical environments, reducing costs and energy consumption [12][13] Industry Impact - Philips is setting new standards in radiation therapy with its innovative solutions, addressing the challenges of accuracy, workflow, and cost in oncology departments [9][13] - The integration of MVision AI's Contour+ software with Philips CT simulators is being explored to enhance automatic delineation of organs at risk [9]